Press Releases

CPhI Japan, the first large pharma event to trade in 2021, played host to 7214 attendees at the exhibition and a further 7204 virtual users from across the globe.  The event, a key marker for the strength of the regional industry, has rebounded quickly with some 216 exhibitors searching for pharma partners. In fact, such has been the demand, CPhI Japan Connect – the event’s digital platform for international audiences – will remain open until the end of May. H

Toxys and Unilever Safety and Environmental Assurance Centre (SEAC) have entered into an agreement to further validate and expand the ReproTracker assay. Testing for developmental toxicity according to the current international guidelines requires large numbers of animals, making these tests very resource-intensive and time-consuming as well as raising ethical concerns. The current ReproTracker in vitro teratogenicity assay has been available to clients since 2020 and monitors the d

Fractyl Laboratories Inc. (Fractyl), a life sciences company dedicated to developing novel therapeutic interventions aimed at reversing the metabolic disease epidemic, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation for Revita® DMR in patients with insulin-treated type 2 diabetes (T2D). Fractyl’s REVITA-T2Di study is now enrolling in this patient population. “We are thrilled to work closely with the FDA to

InveniAI® LLC, a global leader in pioneering the application of Artificial Intelligence (AI) and Machine Learning (ML) to transform innovation across drug discovery and development, today announced a multi-target drug discovery collaboration with Shionogi & Co., Ltd. (Head Office: Osaka, Japan; President and CEO: Isao Teshirogi, Ph.D. hereafter "Shionogi") a global, research-driven pharmaceutical company. The multi-year collaboration will combine InveniAI's AI

Sentia Medical Sciences Inc.announced that they have entered into a research collaboration with Neurocrine Biosciences, Inc. aimed at discovering novel, long-acting corticotropin-releasing factor (CRF) receptor antagonist peptide therapeutics. The collaboration will leverage Sentia’s proprietary peptide-based platform and Neurocrine’s drug development expertise in CRF biology to develop and commercialize medicines with the potential to treat a variety of hypothalamic-pituitary-adr

OSE Immunotherapeutics and Veloxis Pharmaceuticals Inc., a subsidiary of Asahi Kasei,  announced a global license agreement granting Veloxis Pharmaceuticals worldwide rights to develop, manufacture and commercialize FR104, a CD28 antagonist monoclonal antibody fragment, for all transplant indications. In parallel, OSE Immunotherapeutics retains all product rights to develop FR104 in autoimmune diseases. Through this license agreement, Veloxis plans to develop FR104 to provide a new thera

Kintor Pharmaceutical Limited, a clinical-stage biotechnology company developing innovative small molecule and biological therapeutics, announced today that the phase III clinical trial of proxalutamide for the treatment of male patients with mild or moderate COVID-19 symptoms in the United States has completed the first patient enrollment and dosing. Dr. Xunwei Dong, Chief Medical Officer of Kintor Pharmaceutical, commented, "Initiation of this phase III study of proxalutamide

Gilead Sciences K.K. and Eisai Co., Ltd. today announced that Gilead submitted an application to Japan's Pharmaceuticals and Medical Devices Agency (PMDA) for approval of filgotinib for an additional indication to treat patients with moderately to severely active ulcerative colitis. Filgotinib is a new oral Janus kinase (JAK) inhibitor approved in Japan in September 2020 for the treatment of rheumatoid arthritis. This latest regulatory submission is based on data from the random

Candel Therapeutics, Inc., a late clinical stage biopharmaceutical company developing novel oncolytic viral immunotherapies, announced it has completed enrollment for its Phase 1 clinical trial in patients with newly diagnosed high-grade glioma to evaluate the safety and efficacy of CAN-2409 in combination with immune checkpoint inhibitor Opdivo® (nivolumab) and standard of care radiation therapy, as well as temozolomide for patients with methylated MGMT promoters. The trial enrolled 35 e

Illumina, Inc. and Kartos Therapeutics, Inc. are pleased to announce a new partnership to co-develop a TP53 companion diagnostic (CDx) based on the content of Illumina’s comprehensive genomic profiling assay, TruSight™ Oncology 500 (TSO 500). This companion diagnostic for multiple hematologic indications will be the first to use TSO 500 with peripheral whole blood as a diagnostic sample type. “With this partnership, Illumina will expand the TruSight Oncology offeri